Skip to main content
Journal cover image

The ADAPTABLE Trial and Aspirin Dosing in Secondary Prevention for Patients with Coronary Artery Disease.

Publication ,  Journal Article
Johnston, A; Jones, WS; Hernandez, AF
Published in: Curr Cardiol Rep
August 2016

Coronary artery disease (CAD) is the underlying cause of death in one out of seven deaths in the USA. Aspirin therapy has been proven to decrease mortality and major adverse cardiovascular events in patients with CAD. Despite a plethora of studies showing the benefit of aspirin in secondary prevention of cardiovascular events, debate remains regarding the optimal dose due to relatively small studies that had disparate results when comparing patients taking different aspirin dosages. More recently, aspirin dosing has been thoroughly studied in the CAD population with concomitant therapy (such as P2Y12 inhibitors); however, patients in these studies were not randomized to aspirin dose. No randomized controlled trial has directly measured aspirin dosages in a population of patients with established coronary artery disease. In 2015, the Patient-Centered Outcomes Research Institute (PCORI) developed a network, called PCORnet, that includes patient-powered research networks (PPRN) and clinical data research networks (CDRN). The main objective of PCORnet is to conduct widely generalizable observational studies and clinical trials (including large, pragmatic clinical trials) at a low cost. The first clinical trial, called Aspirin Dosing: A Patient-centric Trial Assessing Benefits and Long-term Effectiveness (ADAPTABLE), will randomly assign 20,000 subjects with established coronary heart disease to either low dose (81 mg) or high dose (325 mg) and should be able to finally answer which dosage of aspirin is best for patients with established cardiovascular disease.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Curr Cardiol Rep

DOI

EISSN

1534-3170

Publication Date

August 2016

Volume

18

Issue

8

Start / End Page

81

Location

United States

Related Subject Headings

  • Secondary Prevention
  • Research Design
  • Randomized Controlled Trials as Topic
  • Platelet Aggregation Inhibitors
  • Humans
  • Coronary Artery Disease
  • Clinical Trials as Topic
  • Cardiovascular System & Hematology
  • Aspirin
  • 3201 Cardiovascular medicine and haematology
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Johnston, A., Jones, W. S., & Hernandez, A. F. (2016). The ADAPTABLE Trial and Aspirin Dosing in Secondary Prevention for Patients with Coronary Artery Disease. Curr Cardiol Rep, 18(8), 81. https://doi.org/10.1007/s11886-016-0749-2
Johnston, Abigail, W Schuyler Jones, and Adrian F. Hernandez. “The ADAPTABLE Trial and Aspirin Dosing in Secondary Prevention for Patients with Coronary Artery Disease.Curr Cardiol Rep 18, no. 8 (August 2016): 81. https://doi.org/10.1007/s11886-016-0749-2.
Johnston A, Jones WS, Hernandez AF. The ADAPTABLE Trial and Aspirin Dosing in Secondary Prevention for Patients with Coronary Artery Disease. Curr Cardiol Rep. 2016 Aug;18(8):81.
Johnston, Abigail, et al. “The ADAPTABLE Trial and Aspirin Dosing in Secondary Prevention for Patients with Coronary Artery Disease.Curr Cardiol Rep, vol. 18, no. 8, Aug. 2016, p. 81. Pubmed, doi:10.1007/s11886-016-0749-2.
Johnston A, Jones WS, Hernandez AF. The ADAPTABLE Trial and Aspirin Dosing in Secondary Prevention for Patients with Coronary Artery Disease. Curr Cardiol Rep. 2016 Aug;18(8):81.
Journal cover image

Published In

Curr Cardiol Rep

DOI

EISSN

1534-3170

Publication Date

August 2016

Volume

18

Issue

8

Start / End Page

81

Location

United States

Related Subject Headings

  • Secondary Prevention
  • Research Design
  • Randomized Controlled Trials as Topic
  • Platelet Aggregation Inhibitors
  • Humans
  • Coronary Artery Disease
  • Clinical Trials as Topic
  • Cardiovascular System & Hematology
  • Aspirin
  • 3201 Cardiovascular medicine and haematology